Abstract
Alzheimer’s disease (AD) is characterized by specific alterations of brain DNA methylation (DNAm) patterns. Age and sex, two major risk factors for AD, are also known to largely affect the epigenetic profiles in the brain, but their contribution to AD-associated DNAm changes has been poorly investigated. In this study we considered publicly available DNAm datasets of 4 brain regions (temporal, frontal, entorhinal cortex and cerebellum) from healthy adult subjects and AD patients, and performed a meta-analysis to identify sex-, age- and AD-associated epigenetic profiles. We showed that DNAm differences between males and females tend to be shared between the 4 brain regions, while aging differently affects cortical regions compared to cerebellum. We found that the proportion of sex-dependent probes whose methylation changes also during aging is higher than expected, but that differences between males and females tend to be maintained, with only few probes showing sex-by-age interaction. We did not find significant overlaps between AD- and sex-associated probes, nor disease-by-sex interaction effects. On the contrary, we found that AD-related epigenetic modifications are significantly enriched in probes whose DNAm changes with age and that there is a high concordance between the direction of changes (hyper or hypo-methylation) in aging and AD, supporting accelerated epigenetic aging in the disease.
In conclusion, we demonstrated that age-associated, but not sex-associated DNAm concurs to the epigenetic deregulation observed in AD, providing new insight on how advanced age enables neurodegeneration.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We acknowledge support by the grant of the Ministry of Education and Science of the Russian Federation Agreement No. 075-15-2019-871. This work was supported by the European Union (EU) H2020 Project "PROPAG‐AGEING" (grant agreement 634821) and by the EU JPND "ADAGE".
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Datasets used for the meta-analysis study were downloaded from Gene Expression Omnibus public functional genomics data repository.
Abbreviations
- DNAm
- DNA methylation
- AD
- Alzheimer’s Disease
- DMPs
- differentially methylated positions
- LOAD
- Late Onset Alzheimer’s Disease
- EWAS
- Epigenome-Wide Association Study
- GO
- Gene Ontology
- sDMPs
- sex-associated differentially methylated positions
- aDMPs
- age-associated differentially methylated positions
- s&aDMPs
- sex- and age-associated differentially methylated positions
- LOAD&aDMPs
- Late Onset Alzheimer’s Disease-specific age-associated differentially methylated positions
- LOAD&sDMPs
- Late Onset Alzheimer’s Disease-specific sex-associated variably methylated positions
- LOAD&a&sDMPs
- Late Onset Alzheimer’s Disease-specific sex- and age-associated variably methylated positions
